The prevalence of celiac disease in women with infertility—A systematic review with meta‐analysis
Ida Glimberg, Linnea Haggård, Benjamin Lebwohl and 2 more
Reproductive Medicine and Biology · 2021
doi:10.1002/rmb2.12374 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Abstract Purpose To determine the prevalence of celiac disease in infertile women. Methods A systematic search of four databases was conducted up until February 6, 2020. The search terms “c(o)eliac disease”, “gluten”, “vill(o)us atrophy”, “infertility” and “subfertility” yielded 1142 unique hits. Articles in other languages than English, conference abstracts, letters, and publications where relevant information was missing were excluded. In our main analysis, celiac disease had to be verified by duodenal biopsy. The titles and abstracts, and the full‐text articles were independently reviewed by two researchers. A fixed‐effect model was used to calculate the weighted prevalence. Results Based on 11 studies (1617 women), the pooled prevalence of biopsy‐confirmed celiac disease was 0.7% (95% CI = 0.2%‐1.2%) in women with any infertility. Restricting our study population to women with unexplained infertility, the pooled prevalence of biopsy‐confirmed celiac disease was 0.6% (95% CI = 0.0%‐1.6%). When including studies where celiac disease had been defined per serology (20 studies; 5158 women), the pooled prevalence of celiac disease was 1.1% (95% CI = 0.6%‐1.6%) in women with any infertility. Conclusion Our results indicate that celiac disease is not more common in infertile women than in the general population. Celiac screening in infertile women may have low yield.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.